Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exelixis Inc.

www.exelixis.com

Latest From Exelixis Inc.

Pipeline Watch: Phase III Progress With Avelumab, Ixekizumab And Eravacycline

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Ipsen CEO To Feed Group's Three Therapeutic Engines Fresh Assets In 2018

CEO David Meek Says Ipsen has more than $1bn for M&A use to expand its product line in oncology, neuroscience and rare diseases.

Business Strategies Commercial

Deals Shaping The Medical Industry, February 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.

Deals Medical Device

The Tecentriq/Avastin Combo: Roche Details Renal Cell Cancer Benefits

Roche has continued to drip-feed results from the IMmotion151 Phase III study, this time describing the magnitude of the beneficial responses observed with the first-line use of the Tecentriq-Avastin combination in patients with advanced renal cell cancer.

ImmunoOncology Research & Development
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Exelixis Inc.
  • Senior Management
  • Michael M Morrissey, PhD, Pres. & CEO
    Christopher J Senner, EVP, CFO
    Peter Lamb, PhD, EVP, Scientific Strategy & CSO
    Gisela M Schwab, MD, Pres., Prod. Dev. & CMO
  • Contact Info
  • Exelixis Inc.
    Phone: (650) 837-7000
    210 East Grand Ave.
    P.O. Box 511 S. San Francisco, CA 94083-0511
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register